We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

DefiniGEN Licenses CRISPR-Cas9 Gene Editing Technology from Broad Institute to for Metabolic Disease Drug Development

Product News   Nov 25, 2018

 
DefiniGEN Licenses CRISPR-Cas9 Gene Editing Technology from Broad Institute to for Metabolic Disease Drug Development
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

Horizon Discovery Expands Cell-based CRISPR Screening Services

Product News

Horizon Discovery has announced the addition of an arrayed CRISPR knockout screening service for primary human B cells to its cell-based screening services.

READ MORE

Promega RT-qPCR System Approved for Use in CDC’s COVID-19 Emergency Use Authorization Diagnostic Panel

Product News

The Promega amplification reagent has been added to the EUA list for laboratories that follow CDC’s testing protocols.

READ MORE

Scientists on Standby: Supporting Recruitment of Scientists for COVID-19 Testing

Product News

Scientists on Standby is a portal enabling scientists with relevant skills and experience to volunteer their time, expertise and support for COVID-19 screening and testing.

READ MORE

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE